ArticleJournal of neurochemistry2026
PBMC circRNA Profiles Distinguish Atypical From Idiopathic Parkinsonism and Track Clinical Severity Across Syndromes.
Article in Journal of neurochemistry, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
Early separation of atypical Parkinsonian syndromes (APS) from idiopathic Parkinson's disease (iPD) remains challenging. Given that many brain-biased circular RNAs (circRNAs) are stable and expressed in blood cells, peripheral blood mononuclear cell (PBMC) circRNAs were profiled in 140 individuals (iPD 43, MSA 35, PSP 19, healthy controls 43) using RT-qPCR across 46 a priori candidates. Group differences were analyzed using the Kruskal-Wallis test with FDR correction; clinical associations were examined using Bonferroni-corrected Spearman correlations with a bootstrap stability assessment; and discrimination was assessed using logistic regression with nested repeated cross-validation, calibration analysis, and ROC analysis. Six circRNAs differed across groups after FDR adjustment (SLC8A1_circ_0000994, MAPK9_circ_0001566, MGA_circ_0000591, AGTPBP1_circ_0007162, SFMBT2_circ_0000211, HIPK3_circ_0000284), with median levels lowest in iPD and highest in PSP. Internally cross-validated multi-marker panels achieved AUCs of 0.88 for PSP versus controls, 0.78 for PSP versus iPD, and 0.67 for MSA versus iPD. Several circRNAs, including non-differential ones, showed bootstrap-stable associations with cognitive, mood, working-memory, and praxis measures. ENCORI- and CircInteractome-based analyses placed the differentially expressed circRNAs within a shared RBP interaction landscape and identified modest but significant miRNA-target overlap. Findings indicate that PBMC circRNA patterns aid APS-iPD differentiation and align with clinical impairment within this cohort; external validation, longitudinal assessment, and mechanistic studies are needed to establish diagnostic performance and biological relevance.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.